Clinical Trials for Schizoaffective Disorder
This article provides information about ongoing clinical trials for schizoaffective disorder, a mental health condition that combines symptoms of schizophrenia with mood disturbances. Currently, there are 2 active trials exploring treatment options for people with this condition. These studies are investigating medications and treatment approaches aimed at improving symptoms and quality of life for patients who have not responded well to initial treatments or are starting new therapies.
Clinical trial locations
- Austria
- Czechia
- Germany
- Italy
- Spain
Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure
This trial is designed for people with schizophrenia, schizoaffective disorder, or schizophreniform disorder who have not responded well to their first medication treatment. The study compares an intensified medication approach with the usual treatment to see which works better at reducing symptoms.
Main inclusion criteria:
- Adults between 18 and 70 years old who are either staying in a hospital or visiting as outpatients
- Diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Currently experiencing a first-time treatment failure, meaning the initial medication did not work effectively after at least 4 weeks of use
- Willing to provide written consent to participate, with a legal guardian co-signing if necessary
- Women who can have children must use effective birth control and have a negative pregnancy test
- Must have specific scores showing symptom severity and difficulties with daily functioning
Main exclusion criteria:
- Patients without a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Those who have not experienced a first-time treatment failure
- Individuals outside the specified age range
- People unable or unwilling to follow study procedures
Trial focus and goals:
The study aims to determine whether a six-week intensified medication treatment can reduce symptoms more effectively than standard care for patients who did not respond to their first treatment. The treatment involves a carefully selected combination of medications that are adjusted throughout the study period. Participants will be randomly assigned to either the intensified treatment group or the usual care group. Progress will be measured using the Positive and Negative Syndrome Scale, a tool that assesses symptom severity. The study also monitors anxiety, depression, quality of life, and any side effects that occur during treatment.
Investigational drugs:
The intensified treatment approach includes a variety of medications such as clozapine, ziprasidone, amisulpride, fluoxetine, perphenazine, paliperidone, aripiprazole, risperidone, lurasidone, sertindole, brexpiprazole, cariprazine, and asenapine, among others. The specific combination and dosage will be determined by healthcare professionals based on individual patient needs.
Study on the Safety and Effectiveness of Olanzapine for Patients with Schizophrenia
This clinical trial examines how genetic factors influence the response to olanzapine treatment in patients with psychosis, particularly those diagnosed with schizophrenia or schizoaffective disorders. The study aims to understand why some patients respond better to this medication than others.
Main inclusion criteria:
- Adults between 18 and 60 years old
- Diagnosed with schizophrenia or schizoaffective disorder according to the ICD-10 classification system
- Currently receiving treatment with olanzapine or planning to start it
- Willing to participate and able to provide informed consent
- Women of childbearing potential must use at least one effective method of birth control
Main exclusion criteria:
- Patients with a history of psychoses that do not meet the study criteria
Trial focus and goals:
The study investigates how variations in specific genes, such as CYP1A2, MDR1, 5HT2A, 5HT2C, HDAC3, and HDAC4, affect treatment response to olanzapine. These genetic differences may explain why some patients experience better outcomes than others. Researchers will track symptom improvement, side effects, and the time it takes for patients to respond to treatment. The goal is to provide better understanding of how olanzapine works and how individual genetic makeup can influence treatment success.
Investigational drug:
Olanzapine is an established antipsychotic medication taken as an oral tablet. It works by balancing certain brain chemicals, specifically by blocking dopamine and serotonin receptors. This helps improve mood, thoughts, and behavior in people with psychotic disorders. In this trial, olanzapine is being studied to understand how genetic and epigenetic factors affect its effectiveness.
Summary
Currently, there are two active clinical trials available for patients with schizoaffective disorder. The first trial is being conducted across multiple countries including Germany, Austria, Italy, and Spain, and focuses on patients who have not responded to their initial treatment. It compares an intensified medication approach with standard care using a variety of antipsychotic medications.
The second trial is taking place in Czechia and explores how genetic factors influence treatment response to olanzapine, an established antipsychotic medication. This study aims to personalize treatment by understanding individual genetic differences.
Both trials offer opportunities for patients with schizoaffective disorder to access new treatment approaches and contribute to research that may improve care for others with similar conditions. Patients interested in participating should discuss these options with their healthcare providers to determine if they meet the eligibility criteria.
